IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

被引：180

作者：

Hack, Stephen P. ^{[1
]}

Spahn, Jessica ^{[1
]}

Chen, Minshan ^{[2
]}

Cheng, Ann-Lii ^{[3
,4
]}

Kaseb, Ahmed ^{[5
]}

Kudo, Masatoshi ^{[6
]}

Lee, Han Chu ^{[7
]}

Yopp, Adam ^{[8
]}

Chow, Pierce ^{[9
]}

Qin, Shukui ^{[10
]}

机构：

[1] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA

[2] Sun Yat Sen Univ, Dept Hepatobiliary Surg, Canc Ctr, Guangzhou, Peoples R China

[3] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA

[6] Kindai Univ, Dept Gastroenterol & Hepatol, Sch Med, Osaka, Japan

[7] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Coll Med, Seoul, South Korea

[8] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA

[9] Natl Canc Ctr, Div Surg Oncol, Singapore, Singapore

[10] Peoples Liberat Army PLA 81 Hosp, PLA Canc Ctr, Nanjing 210016, Peoples R China

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 15期

关键词：

ablation; adjuvant treatment; atezolizumab; bevacizumab; hepatocellular carcinoma; PD-L1; recurrence-free survival; resection; VEGF; CYTOTOXIC T-CELLS; SUPPRESSOR-CELLS; LIVER-CANCER; POSTSURGICAL RECURRENCE; RADIOFREQUENCY ABLATION; SURGICAL RESECTION; POOR SURVIVAL; TUMOR VACCINE; HCC PATIENTS; PATIENTS PTS;

D O I：

10.2217/fon-2020-0162

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoints such as PD-L1. Atezolizumab (PD-L1 inhibitor) plus bevacizumab (VEGF inhibitor) has been shown to significantly improve overall survival, progression-free survival and overall response rate in unresectable HCC. Dual PD-L1/VEGF blockade may be effective in reducing HCC recurrence by creating a more immune-favorable microenvironment. We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary end point is recurrence-free survival. Clinical Trial Registration: NCT04102098

引用

页码：975 / 989

页数：15

共 69 条

[1] Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis [J].

Arihara, Fumitaka ;

Mizukoshi, Eishiro ;

Kitahara, Masaaki ;

Takata, Yoshiko ;

Arai, Kuniaki ;

Yamashita, Tatsuya ;

Nakamoto, Yasunari ;

Kaneko, Shuichi .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (08) :1421-1430

[2] Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy [J].

Aufhauser, David D., Jr. ;

Sadot, Eran ;

Murken, Douglas R. ;

Eddinger, Kevin ;

Hoteit, Maarouf ;

Abt, Peter L. ;

Goldberg, David S. ;

DeMatteo, Ronald P. ;

Levine, Matthew H. .

ANNALS OF SURGERY, 2018, 267 (05) :922-928

[3] Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy [J].

Brown, Zachary J. ;

Greten, Tim F. ;

Heinrich, Bernd .

HEPATOLOGY, 2019, 70 (04) :1437-1442

[4] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial [J].

Bruix, Jordi ;

Takayama, Tadatoshi ;

Mazzaferro, Vincenzo ;

Chau, Gar-Yang ;

Yang, Jiamei ;

Kudo, Masatoshi ;

Cai, Jianqiang ;

Poon, Ronnie T. ;

Han, Kwang-Hyub ;

Tak, Won Young ;

Lee, Han Chu ;

Song, Tianqiang ;

Roayaie, Sasan ;

Bolondi, Luigi ;

Lee, Kwan Sik ;

Makuuchi, Masatoshi ;

Souza, Fabricio ;

Le Berre, Marie-Aude ;

Meinhardt, Gerold ;

Llovet, Josep M. .

LANCET ONCOLOGY, 2015, 16 (13) :1344-1354

[5] Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features [J].

Calderaro, Julien ;

Rousseau, Benoit ;

Amaddeo, Giuliana ;

Mercey, Marion ;

Charpy, Cecile ;

Costentin, Charlotte ;

Luciani, Alain ;

Zafrani, Elie-Serge ;

Laurent, Alexis ;

Azoulay, Daniel ;

Lafdil, Fouad ;

Pawlotsky, Jean-Michel .

HEPATOLOGY, 2016, 64 (06) :2038-2046

[6] The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages [J].

Capece, Daria ;

Fischietti, Mariafausta ;

Verzella, Daniela ;

Gaggiano, Agata ;

Cicciarelli, Germana ;

Tessitore, Alessandra ;

Zazzeroni, Francesca ;

Alesse, Edoardo .

BIOMED RESEARCH INTERNATIONAL, 2013, 2013

[7] Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection [J].

Chan, Anthony W. H. ;

Zhong, Jianhong ;

Berhane, Sarah ;

Toyoda, Hidenori ;

Cucchetti, Alessandro ;

Shi, KeQing ;

Tada, Toshifumi ;

Chong, Charing C. N. ;

Xiang, Bang-De ;

Li, Le-Qun ;

Lai, Paul B. S. ;

Mazzaferro, Vincenzo ;

Garcia-Finana, Marta ;

Kudo, Masatoshi ;

Kumada, Takashi ;

Roayaie, Sasan ;

Johnson, Philip J. .

JOURNAL OF HEPATOLOGY, 2018, 69 (06) :1284-1293

[8] Combinations of Bevacizumab With Cancer Immunotherapy [J].

Chen, Daniel S. ;

Hurwitz, Herbert .

CANCER JOURNAL, 2018, 24 (04) :193-204

[9]

Cheng AL, 2019, Ann Oncol, V30, pix186

[10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

← 1 2 3 4 5 6 7 →